Factors affecting the uptake of new medicines: a systematic literature review

BMC Health Services Research

Ágnes Lublóy¹ 

[1] Department of Finance, Institute of Finance and Accounting, Corvinus University of Budapest, Fővám tér 8, Budapest 1093, Hungary

关键词: Systematic literature review;    Social networks of doctors;    Prescriber characteristics;    Practice characteristics;    Pharmaceutical marketing;    Patient characteristics;    New drugs;    Early adopters;    Drug characteristics;    Diffusion;   

Others  :  1118382
DOI  :  10.1186/1472-6963-14-469

 received in 2014-01-19, accepted in 2014-09-24,  发布年份 2014

【 摘 要 】

Background

The successful diffusion of new drugs is crucial for both pharmaceutical companies and patients—and of wider stakeholder concern, including for the funding of healthcare provision. Micro-level characteristics (the socio-demographic and professional characteristics of medical professionals), meso-level characteristics (the prescribing characteristics of doctors, the marketing efforts of pharmaceutical companies, interpersonal communication among doctors, drug attributes, and the characteristics of patients), and macro-level characteristics (government policies) all influence the diffusion of new drugs. This systematic literature review examines the micro- and meso-level characteristics of early prescribers of newly introduced drugs. Understanding the characteristics of early adopters may help to speed up the diffusion process, promote cost-efficient prescribing habits, forecast utilisation, and develop targeted intervention strategies.

Methods

The PubMed and Scopus electronic databases were chosen for their extensive coverage of the pertinent literature and used to identify 205 potentially relevant studies by means of a four-layered search string. The 35 studies deemed eligible were then synthetized carefully and critically, to extract variables relevant to this review.

Results

Early adoption of new drugs is not a personal trait, independent of drug type, but early adopters share both micro- and meso-level characteristics. At prescriber level, doctors’ interest in particular therapeutic areas, participation in clinical trials, and volume of prescribing—either in total or within the therapeutic class of the new drug—increase the likelihood of early adoption. The marketing efforts of pharmaceutical companies and doctors’ professional and social interactions leading to prescribing contagion are very powerful predictors of new drug uptake. At patient level, doctors with younger patients, patients with higher socioeconomic statuses and/or patients with poorer health statuses are more inclined to prescribe new drugs early. In contrast, the socio-demographic characteristics of prescribers and many practice-related factors play little role in the adoption process.

Conclusions

The most powerful predictors of new drug uptake include the doctors’ strong scientific commitment, high prescribing volume in total or in within the therapeutic class of the new drug, high exposure to marketing, and intense communication with colleagues.

【 授权许可】

   
2014 Lublóy; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Tamblyn R, McLeod P, Hanley JA, Girard N, Hurley J: Physician and practice characteristics associated with the early utilization of new prescription drugs. Med Car 2003, 41:895-908.
• [2]Walley T, Mrazek M, Mossialos E: Regulating pharmaceutical markets: improving efficiency and controlling costs in the UK. Int J Health Plann Manage 2005, 20:375-398.
• [3]Food and Drug Administration (FDA): Summary of FDA Approvals & Receipts, 1938 to the present. FDA; 2014. Retrieved 10 September, 2014, from http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SummaryofNDAApprovalsReceipts1938tothepresent/default.htm webcite
• [4]Berwick DM: Disseminating innovations in health care. JAMA 2003, 289:1969-1975.
• [5]Ohlsson H, Chaix B, Merlo J: Therapeutic traditions, patient socioeconomic characteristics and physicians’ early new drug prescribing: a multilevel analysis of rosuvastatin prescription in South Sweden. Eur J Clin Pharmacol 2009, 65:141-150.
• [6]Groves KEM, Schellinck T, Sketris I, MacKinnon NJ: Identifying early prescribers of cycloxygenase-2 inhibitors (COX-2 s) in Nova Scotia, Canada: considerations for targeted academic detailing. Res Social Adm Pharm 2010, 6:257-267.
• [7]Coleman JS, Katz E, Menzel H: Medical Innovation: A Diffusion Study. New York: Bobbs-Merrill Company; 1966.
• [8]McGettigan P, Golden J, Fryer J, Chan R, Feely J: Prescribers prefer people: the sources of information used by doctors for prescribing suggest that the medium is more important than the message. Br J Clin Pharmacol 2001, 51:184-189.
• [9]West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A: Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995, 142:1103-1112.
• [10]Prosser H, Walley T: New drug prescribing by hospital doctors: the nature and meaning of knowledge. Soc Sci Med 2006, 62:1565-1578.
• [11]Greving JP, Denig P, Van Der Veen WJ, Beltman FW, Sturkenboom MCJM, Haaijer-Ruskamp FM: Determinants for the adoption of angiotensin II receptor blockers by general practitioners. Soc Sci Med 2006, 63:2890-2898.
• [12]Iyengar R, Van den Bulte C, Valente TW: Opinion leadership and social contagion in new product diffusion. Market Sci 2011, 30:195-212.
• [13]Liu Q, Gupta S: A micro-level diffusion model for new drug adoption. J Prod Innovat Manag 2012, 29:372-384.
• [14]Mark TL, Dirani R, Slade E, Russo PA: Access to new medications to treat schizophrenia. J Behav Health Ser R 2002, 29:15-29.
• [15]Van den Bulte C, Lilien GL: Medical innovation revisited: social contagion versus marketing effort. Am J Sociol 2001, 106:1409-1435.
• [16]Álvárez MJL, Hernández MJR: Variabilidad en la utilización de nuevos medicamentos en un área de atención primaria (in Spanish with English abstract). Rev Es Salud Public 2005, 79:379-389.
• [17]Behan K, Cutts C, Tett SE: Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors. Eur J Clin Pharmacol 2005, 61:55-58.
• [18]Bourke J, Roper S: In with the new: the determinants of prescribing innovation by general practitioners in Ireland. Eur J Health Econ 2012, 13:393-407.
• [19]Corrigan MH, Glass HE: Physician participation in clinical studies and subsequent prescribing of new drugs. P&T 2005, 30:60-66.
• [20]Dybdahl T, Andersen M, Søndergaard J, Kragstrup J, Kristiansen IS: Does the early adopter of drugs exist? A population-based study of general practitioners’ prescribing of new drugs. Eur J Clin Pharmacol 2004, 60:667-672.
• [21]Dybdahl T, Andersen M, Kragstrup J, Kristiansen IS, Søndergaard J: General practitioners’ adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study. Br J Clin Pharmacol 2005, 60:526-533.
• [22]Dybdahl T, Søndergaard J, Kragstrup J, Kristiansen IS, Andersen M: Primary care physicians’ adoption of new drugs is not associated with their clinical interests: a pharmacoepidemiologic study. Scand J Prim Health 2011, 29:117-121.
• [23]Florentinus SR, Van Hulten R, Kloth ME, Heerdink ER, Griens AF, Leufkens HG, Groenewegen PP: The effect of pharmacotherapy audit meetings on early new drug prescribing by general practitioners. Ann Pharmacother 2007, 41:319-324.
• [24]García LM, Cabeza BJ, Rodríguez EM, Alegre DRE, Rabadán AA: Adoption of new medications by prescribing physicians: the innovator physician. Aten Prim 2000, 25:22-28.
• [25]Garjón FJ, Azparren A, Vergara I, Azaola B, Loayssa JR: Adoption of new drugs by physicians: a survival analysis. BMC Health Serv Res 2012, 12:56. BioMed Central Full Text
• [26]Glass HE: Physician participation in market support clinical studies and subsequent prescribing behaviour. J Pharm Mark Manage 2003, 15:3-16.
• [27]Glass HE: Do clinical grant payment practices in phase 3 clinical trials influence subsequent clinical investigator prescribing behavior? Dis Manag 2004, 7:77-87.
• [28]Glass HE, Rosenthal B: Demographics, practices, and prescribing characteristics of physicians who are early adopters of new drugs. P&T 2004, 29:2-8.
• [29]Glass HE, Rosenthal B: Post-launch clinical investigator drug prescribing in the US. Int J Pharm Med 2005, 19:97-104.
• [30]Glass HE, Dalton DW: Profiles of phase IV investigators and subsequent prescribing of the study drug. J Pharm Mark Manage 2006, 17:3-17.
• [31]Griffin JP, Griffin TD: The economic implications of therapeutic conservatism. J Roy Coll Phys Lond 1993, 27:121-125.
• [32]Helin-Salmivaara A, Huupponen R, Virtanen A, Klaukka T: Adoption of celecoxib and rofecoxib: a nationwide database study. J Clin Pharm Ther 2005, 30:145-152.
• [33]Huskamp HA, O’Malley AJ, Horvitz-Lennon M, Taub AL, Berndt ER, Donohue JM: How quickly do physicians adopt new drugs? The case of second-generation antipsychotics. Psychiatr Serv 2013, 64:324-330.
• [34]Inman W, Pearce G: Prescriber profile and post-marketing surveillance. Lancet 1993, 342:658-661.
• [35]Kozyrskyj A, Raymond C, Racher A: Characterizing early prescribers of newly marketed drugs in Canada: a population-based study. Eur J Clin Pharmacol 2007, 63:597-604.
• [36]Lin SJ, Jan KA, Kao JT: Colleague interactions and new drug prescribing behavior: the case of the initial prescription of antidepressants in Taiwanese medical centers. Soc Sci Med 2011, 73:1208-1213.
• [37]Liu YM, Kao Yang YH, Hsieh CR: The determinants of the adoption of pharmaceutical innovation: evidence from Taiwan. Soc Sci Med 2011, 72:919-927.
• [38]Manchanda P, Xie Y, Youn N: The role of targeted communication and contagion in product adoption. Market Sci 2008, 27:961-976.
• [39]Mizik N, Jacobson R: Are physicians “easy marks”? Quantifying the effects of detailing and sampling on new prescriptions. Manage Sci 2004, 50:1704-1715.
• [40]Steffensen FH, Sörensen H, Olesen F: Diffusion of new drugs in Danish general practice. Fam Pract 1999, 16:407-413.
• [41]Ruof J, Mittendorf T, Pirk O, Von Der Schulenburg JM: Diffusion of innovations: treatment of Alzheimer’s disease in Germany. Health Policy 2002, 60:59-66.
• [42]Jones MI, Greenfield SM, Bradley CP, Jowett S: Prescribing new drugs: a survey of hospital consultants in the West Midlands. Int J Pharm Pract 2000, 8:285-290.
• [43]Jacoby A, Smith M, Eccles M: A qualitative study to explore influences on general practitioners’ decisions to prescribe new drugs. Br J Gen Pract 2003, 53:120-125.
• [44]Prosser H, Walley T: New drug uptake: qualitative comparison of high and low prescribing GPs’ attitudes and approach. Fam Pract 2003, 20:583-591.
• [45]American Board of Physician Specialties (ABPS): Physician Board Certification Defined. 2013. Retrieved 20 November, 2013, from http://www.abpsus.org/physician-board-certification-defined webcite
• [46]Peay MY, Peay ER: Patterns of preference for information sources in the adoption of new drugs by specialists. Soc Sci Med 1990, 31:467-476.
• [47]Chauhan D, Mason A: Factors affecting the uptake of new medicines in secondary care: a literature review. J Clin Pharm Ther 2008, 33:339-348.
• [48]Manchanda P, Honka E: Effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. Yale J Health Policy Law Ethics 2005, 5:785-822.
• [49]Prosser H, Almond S, Walley T: Influence on GPs’ decision to prescribe new drugs: the importance of who says what. Fam Pract 2003, 20:61-68.
• [50]Peay MY, Peay ER: Innovation in high risk drug therapy. Soc Sci Med 1994, 39:39-52.
• [51]Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM: Promotion of prescription drugs to consumers. N Engl J Med 2002, 346:498-505.
• [52]Groves KEM, Flanagan PS, MacKinnon NJ: Why physicians start or stop prescribing a drug: literature review and formulary implications. Formulary 2002, 37:186-194.
• [53]Burt RS: Social contagion and innovation: cohesion versus structural equivalence. Am J Sociol 1987, 92:1287-1335.
• [54]Kremer S, Bijmolt TH, Leeflang PS, Wieringa JE: Generalizations on the effectiveness of pharmaceutical promotional expenditures. Inf J Res Mark 2008, 25:234-246.
• [55]Azoulay P: Do pharmaceutical sales respond to scientific evidence? J Econ Manage Strat 2002, 11:551-594.
• [56]Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T: An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts. J Ment Health Policy 2002, 5:3-20.
• [57]Cleary JD: Impact of pharmaceutical sales representatives on physician antibiotic prescribing. J Pharm Technol 1992, 8:27-29.
• [58]Lilien GL, Rao AG, Kalish S: Bayesian estimation and control of detailing effort in a repeat purchase diffusion environment. Manage Sci 1981, 27:493-506.
• [59]Gönül FF, Carter F, Petrova E, Srinivasan K: Promotion of prescription drugs and its impact on physicians’ choice behaviour. J Market 2001, 65:79-90.
• [60]Manchanda P, Chintagunta PK: Responsiveness of physician prescription behavior to salesforce effort: an individual level analysis. Market Lett 2004, 15:129-145.
• [61]Manchanda P, Rossi PE, Chintagunta PK: Response modeling with nonrandom marketing-mix variables. J Market Res 2004, 42:467-478.
• [62]Gilbody S, Wilson P, Watt I: Benefits and harms of direct to consumer advertising: a systematic review. Qual Saf Health Care 2005, 14:246-250.
• [63]Donohue JM, Berndt ER: Effects of direct-to-consumer advertising on medication choice: the case of antidepressants. J Public Policy Mark 2004, 23:115-127.
• [64]Iizuka T, Jin GZ: Direct to consumer advertising and prescription choice. J Ind Econ 2007, 55:771.
• [65]Narayanan S, Desiraju R, Chintagunta PK: Return on investment implications for pharmaceutical promotional expenditures: the role of marketing-mix interactions. J Marketing 2004, 68:90-105.
• [66]Wosińska M: Just what the patient ordered? Direct-to-consumer advertising and the demand for pharmaceutical products. Harvard Business School Marketing Research Papers, Volume No. 02–04 2002.
• [67]Rosenthal MB, Berndt ER, Donohue JM, Epstein AM, Frank RG: Demand effects of recent changes in prescription drug promotion. Frontiers Health Policy Res 2003, 6:1-26.
• [68]Williamson PM: The adoption of new drugs by doctors practising in group and solo practice. Soc Sci Med 1975, 9:233-236.
• [69]Weiss R, Charney E, Baumgardner RA, German PS, Mellits ED, Skinner EA, Williamson JW: Changing patient management: what influences the practicing pediatrician? Pediatrics 1990, 85:791-795.
• [70]Van den Bulte C, Lilien GL: Two-stage partial observability models of innovation adoption. In Working Paper. University of Pennsylvania, Wharton School; 2001. [http://www.uvm.edu/~pdodds/files/papers/others/2001/vandenbulte2001a.pdf webcite]
• [71]Mason A: New medicines in primary care: a review of influences on general practitioner prescribing. J Clin Pharm Ther 2008, 33:1-10.
• [72]Tobin L, Almedia Neto AC, Wutzke S, Patterson C, Mackson J, Weekes L, Williamson M: Influences on the prescribing of new drugs. Aust Fam Physician 2008, 37:78-81.
• [73]Winkleby MA, Jatulis DE, Frank E, Fortmann SP: Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. Am J Public Health 1992, 82:816-820.
• [74]Bensing JM, Van Den Brink-Muinen A, De Bakker DH: Gender differences in practice style: a Dutch study of general practitioners. Med Car 1993, 31:219-229.
• [75]Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau ME: International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol 2012, 19:e165.
• [76]Godman B, Wettermark B, Van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, Gustafsson LL: Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol 2014, 5:106.
• [77]Gustafsson LL, Wettermark B, Godman B, Andersén‒Karlsson E, Bergman U, Hasselström J, von Bahr C: The ‘wise list’–a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011, 108:224-233.
• [78]Björkhem-Bergman L, Andersén-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, Gustafsson LL: Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol 2013, 69:73-78.
• [79]Pham HH, O’Malley AS, Bach PB, Saiontz-Martinez C, Schrag D: Primary care physicians’ links to other physicians through Medicare patients: the scope of care coordination. An Intern Med 2009, 150:236-242.
• [80]Barnett ML, Landon BE, O’Malley AJ, Keating NL, Christakis NA: Mapping physician networks with self-reported and administrative data. Health Serv Res 2011, 46:1592-1609.
• [81]Landon BE, Keating NL, Barnett ML, Onnela JP, Paul S, O’Malley AJ, Keegan T, Christakis NA: Variation in patient-sharing networks of physicians across the United States. JAMA 2012, 308:265-273.
• [82]Florentinus SR, Heerdink ER, Van Dijk L, Griens AMGF, Groenewegen PP, Leufkens HGM: Is new drug prescribing in primary care specialist induced? BMC Health Serv Res 2009, 9:6. BioMed Central Full Text
• [83]Avorn J, Chen M, Hartley R: Scientific versus commercial sources of influence on the prescribing behaviour of physicians. Am J Med 1982, 73:4-8.
• [84]Peay MY, Peay ER: The role of commercial sources in the adoption of a new drug. Soc Sci Med 1988, 26:1183-1189.